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ABSTRACT 
Data on the extent and clinical significance of cardiovascular abnormalities in primary 
hyperparathyroidism (PHPT) are conflicting. The main objective of this thesis was to 
evaluate the cardiovascular function in patients with mild PHPT without other known 
risk factors and to analyze the effect of parathyroid adenomectomy. Our second aim 
was to analyze whether an elevated parathyroid hormone level induces any acute effect 
on endothelial function. 
 
In a prospective case-control design, 51 consecutive PHPT patients without any known 
cardiovascular risk factor were compared to 51 randomly enrolled healthy controls. The 
patients were re-examined 15±4 months after parathyroid adenomectomy, when 
parathyroid hormone and calcium levels had normalized. Vitamin D deficiency, 
defined as 25-OH-D < 50 nmol/L, was found in 77% of the patients compared to 20% 
of the controls; 40% of the PHPT patients were still vitamin D deficient at follow-up. 
Systolic blood pressure and triglyceride levels were higher in cases compared to 
controls and decreased after parathyroid adenomectomy. Cardiac morphology and 
function, evaluated by echocardiography and Doppler tissue imaging, were normal in 
both groups but the systolic myocardial velocities were higher in the PHPT group at 
baseline. Both systolic and diastolic blood pressure correlated to the PTH and calcium 
levels. Structural properties and function of the carotid and radial arteries, evaluated by 
ultrasound and pulse-wave analysis, were normal in both groups and did not change 
after parathyroid adenomectomy. Biomarkers of inflammation, coagulation and 
endothelial function were normal in both groups. The forearm blood flow response to 
metacholin and nitroprusside, analyzed in young healthy subjects, was not altered 
during parathyroid hormone infusion.  
 
In conclusion, patients with mild PHPT without known cardiovascular risk factors had 
normal cardiovascular structure and function but a higher systolic myocardial 
performance at baseline which decreased after parathyroid adenomectomy. Vitamin D 
deficiency was more common in cases. Parathyroid adenomectomy had an overall 
positive effect on blood pressure, vitamin D status and triglyceride level. However, 
based on our results, we have no evidence that cardiovascular complications can be 
prevented by parathyroid surgery in PHPT patients without known cardiovascular 
diseases and risk factors. We registered no vasoactive effect mediated by PTH alone. 
  
LIST OF PUBLICATIONS 
This thesis is based on the following original studies, which will be referred to in the 
text by their Roman numerals: 
 
 
I. Farahnak P, Lind
 
L, Marttala
 
K, Nilsson
 
I-L. Parathyroid Hormone’s Acute 
Effect on Vasodilatory Function. Clinical Medicine Insights: Endocrinology 
and Diabetes 2010;3:37–42. 
  
II. Farahnak P, Ring M, Caidahl K, Farnebo L-O, Eriksson M J, Nilsson
 
I-L. 
Cardiac function in mild primary hyperparathyroidism and the outcome after 
parathyroidectomy. European Journal of Endocrinology 2010;163: 461–467. 
  
III. Ring M, Farahnak P, Gustavsson T,
 
Nilsson I-L,
 
Eriksson M J,
 
Caidahl K. 
Arterial structure and function in mild primary hyperparathyroidism before 
and after parathyroidectomy. Manuscript. 
  
IV. Farahnak P, Lärfars G, Sten-Linder M, Nilsson I-L. Mild primary 
hyperparathyroidism: Vitamin D deficiency and cardiovascular risk markers. 
Accepted. 
 
  
CONTENTS 
1 Introduction ................................................................................................... 1 
1.1 Background ......................................................................................... 1 
1.2 Diagnosis and clinical presentation of PHPT .................................... 1 
1.3 Parathyroid hormone .......................................................................... 3 
1.4 Calcium ............................................................................................... 3 
1.5 Vitamin D ............................................................................................ 4 
1.6 PTH and the cardiovascular system ................................................... 5 
1.7 Calcium and the cardiovascular system ............................................. 5 
1.8 Cardiovascular manifestations in PHPT ............................................ 6 
1.8.1 Mortality ................................................................................. 6 
1.8.2 Cardiac structure and function ............................................... 6 
1.8.3 Vascular structure and function ............................................. 7 
1.8.4 Hypertension ........................................................................... 8 
1.9 Vitamin D and PHPT .......................................................................... 8 
1.10 Lipoprotein disturbances in PHPT ................................................. 9 
1.11 Cardiovascular risk markers ........................................................... 9 
1.12 Treatment of primary hyperparathyroidism ................................. 11 
2 Aims of the thesis ....................................................................................... 12 
3 Material and methods ................................................................................. 13 
3.1 Subjects and study design ................................................................. 13 
3.1.1 Study I ................................................................................... 13 
3.1.2 Studies II–IV ........................................................................ 13 
3.2 Methods ............................................................................................. 14 
3.2.1 Forearm blood flow measurement (study I) ........................ 14 
3.2.2 Experimental procedure (study I) ........................................ 15 
3.2.3 Intra-arterial infusion of PTH (study I)................................ 16 
3.2.4 Blood pressure, BMI and GFR (studies II–IV) ................... 16 
3.2.5 Body surface area (studies II and III) .................................. 17 
3.2.6 Echocardiography (study II) ................................................ 17 
3.2.7 Doppler tissue imaging (study II) ........................................ 18 
3.2.8 Carotid artery ultrasound (study III) .................................... 19 
3.2.9 High resolution ultrasound of the radial artery (study III) .. 20 
3.2.10 Pulse-wave analysis (study III) ............................................ 21 
3.3 Image analyses .................................................................................. 22 
3.3.1 Study II ................................................................................. 22 
3.3.2 Study III ................................................................................ 22 
3.4 Laboratory methods .......................................................................... 22 
3.4.1 Study I ................................................................................... 22 
3.4.2 Studies II–IV ........................................................................ 23 
3.5 Statistics ............................................................................................ 23 
4 Results ......................................................................................................... 25 
4.1 FBF measurement and biochemical data (Study I) ......................... 25 
4.2 Clinical and biochemical data (Studies II–IV) ................................ 26 
4.3 Echocardiography (study II) ............................................................. 28 
4.4 Vascular ultrasound and Pulse-wave analysis ................................. 31 
  
(study III) .................................................................................................... 31 
4.5 Vitamin D and cardiovascular risk markers (study IV) .................. 32 
5 Discussion ................................................................................................... 36 
5.1 Study I ............................................................................................... 36 
5.2 Study II ............................................................................................. 37 
5.3 Study III ............................................................................................ 38 
5.4 Study IV ............................................................................................ 39 
5.5 General discussion ............................................................................ 40 
5.6 Future perspectives ........................................................................... 42 
6 Conclusions ................................................................................................ 43 
7 Populärvetenskaplig sammanfattning (Swedish summary) ...................... 44 
8 Acknowledgements .................................................................................... 46 
9 References .................................................................................................. 48 
 
  
LIST OF ABBREVIATIONS 
 
1,25(OH)2D 1,25 dihydroxyvitamin D 
25-OH-D 25-hydroxyvitamin D 
A Peak transmitral diastolic flow velocity during atrial contraction 
A´ Peak late diastolic velocity recorded by DTI 
AI Augmentation index 
ALP Alkaline phosphatase 
Apo Apolipoprotein 
AV-plane Atrioventricular plane 
BMI Body mass index  
BMD Bone mineral density 
BP Blood pressure 
BSA Body surface area 
Ca++ Ionized calcium 
CaSR Calcium sensing receptors 
CCA Common carotid artery 
CV Cardiovascular 
DBP Diastolic blood pressure 
DTI Doppler tissue imaging 
DT Deceleration time 
E Early transmitral diastolic flow 
E´ Peak early diastolic velocities recorded by DTI 
EF Ejection fraction 
EFI Endothelial function index 
EDV Endothelium-dependent vasodilation 
EIDV Endothelium-independent vasodilation 
FHH Familial hypocalciuric hypercalcemia 
FBF Forearm blood flow 
FS Fractional shortening 
GFR Glomerular filtration rate 
HDL High density lipoprotein 
hs-CRP High sensitive C-reactive protein 
IGF-1 Insulin-like growth factor 1 
IM-GSM Intima media grey scale median 
IMTcca Intima media thickness in common carotid artery 
IMTrad Intima media thickness in the radial artery 
IRMA Immunoradiometric assay 
IVRT Isovolumic relaxation time 
LV Left ventricular 
LVDd Left ventricular end-diastolic diameter 
LVDs Left ventricular end-systolic diameter 
LVH Left ventricular hypertrophy 
LVMI Left ventricular mass index 
IVSd End-diastolic interventricular septum thickness 
LDL Low density lipoprotein 
  
MCh Metacholine 
PAI-1 Plasminogen activator inhibitor-1 
PHPT Primary hyperparathyroidism 
PTH  Parathyroid hormone 
PTHrP PTH-related protein 
PTX Parathyroid adenomectomy 
PWA Pulse-wave analysis 
PWTd End-diastolic left ventricular posterior wall thickness 
RV Right ventricle  
RVDd Right ventricular end-diastolic diameter 
S´ Peak systolic velocities recorded by DTI 
SBP Systolic blood pressure 
SD Standard deviation 
SNP Sodium nitroprusside 
TG Triglycerides  
VWF Von Willebrand factor 
 
    1 
1 INTRODUCTION 
 
1.1 BACKGROUND 
Primary hyperparathyroidism (PHPT) is a common endocrine disorder, characterized 
by a high-normal serum calcium concentration and an inappropriately increased 
parathyroid hormone (PTH) level. PHPT is caused by a single adenoma in 80–85% of 
the patients, while multiglandular parathyroid disease (hyperplasia or multiple 
adenomas) is found in 15–20 % and carcinoma is rare, less than 1% 1. The introduction 
of automated methods for the determination of serum calcium in recent decades has led 
to a dramatic increase in the number of diagnosed cases of PHPT. The prevalence of 
PHPT is about 1% in the adult population, with a female dominance of 3–4:1; it 
increases with age in both sexes and is highest in postmenopausal women, 3–4% 2, 3. 
 
PHPT was classically known as a disease of “bones, stones, abdominal groans and 
psychiatric moans” and was associated with severe skeletal and renal complications and 
apparent mortality. Today, the majority of patients with newly diagnosed PHPT show 
none of the classic symptoms or signs traditionally associated with the disease and the 
condition is often defined as a mild asymptomatic disorder. PHPT has been associated 
with impaired glucose tolerance, lipid metabolic disturbances, increased cardiovascular 
(CV) morbidity and premature death in CV and malignant disorders 
4-8
. It has been 
argued that the risk of CV complications is coupled to more severe disease and the 
extent and the nature of CV involvement in those with mild disease are still unclear 
9
. 
Our knowledge of CV disturbances in PHPT is mostly based on data from cohorts with 
varying disease severity and pre-existing CV risk factors that explain the discrepant 
findings in the literature. The Third International Workshop on the Management of 
Asymptomatic Primary Hyperparathyroidism recently reviewed the evidence for 
management of mild asymptomatic PHPT and requested prospective cohort studies of 
parathyroid adenomectomy’s (PTX’s) impact on CV aspects of PHPT 9. 
 
1.2 DIAGNOSIS AND CLINICAL PRESENTATION OF PHPT 
The diagnostic hallmark of PHPT is hypercalcemia in combination with high or non-
suppressed levels of PTH. However, the biochemical spectrum of PHPT varies greatly 
between individuals. Some patients have a PTH level that is within the reference range 
but still inappropriately high relative to the hypercalcemia, while others have a so-
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called normocalcemic PHPT in which an elevated PTH is combined with a consistently 
normal calcium level. The diagnosis of normocalcemic PHPT requires that other causes 
of secondary hyperparathyroidism, such as vitamin D deficiency or renal insufficiency, 
have been excluded 
9
. In a large prospective study with 10,000 patients with surgically 
proven PHPT, PTH levels remained within the normal range (on average) in 16.5% of 
the patients and normocalcemic PHPT was found in 2.5% 
10
.   
 
Conditions other than PHPT may also lead to disturbances in PTH and calcium levels. 
The most frequent other cause of hypercalcemia is malignancy. Measurement of intact 
PTH has resulted in substantially improved diagnostic discrimination since in 
malignancy-related hypercalcemia, PTH levels are characteristically suppressed 
11
. Less 
commonly, hypercalcemia is due to granulomatous diseases 
12
, immobilisation 
13
 or 
drugs such as lithium 
14
 or thiazide diuretics 
15
. Another differential diagnostic 
consideration in PHPT is familial hypocalciuric hypercalcemia (FHH), an autosomal 
dominant disorder caused by inactivating mutations of the calcium-sensing receptor 
(CaSR), which makes the parathyroid glands less sensitive to calcium. FHH can be 
distinguished from PHPT by measuring the calcium/creatinine clearance ratio in urine, 
which is less than 0.01 in FHH and more than 0.02 in patients with PHPT. When the 
diagnosis is in doubt, CaSR gene sequence testing can be obtained 
16
.  
 
In most cases, PHPT is a sporadic disease; a history of cervical irradiation is a 
recognized risk factor but the exact cause is unknown in the majority of cases. In less 
than 1%, PHPT is part of a defined hereditary syndrome such as multiple endocrine 
neoplasia (MEN) type 1 or 2, hyperparathyroidism-jaw tumour syndrome and familial 
isolated hyperparathyroidism 
16
.  
 
The disease’s clinical profile has changed dramatically in recent decades. Nowadays, at 
least in the Western world, the disorder is often detected by chance in almost 
asymptomatic patients. Even though the majority of patients with PHPT have no 
obvious symptoms or signs, many of them are reported to present non-specific 
neuropsychological symptoms such as weakness, easy fatigability, depression, 
cognitive impairment and irritability affecting the quality of life 
17
. Overt skeletal and 
renal diseases are rare but the prevalence of nephrolithiasis and osteoporosis with 
related fracture is higher in PHPT patients compared to the healthy population 
18-21
.  
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1.3 PARATHYROID HORMONE  
PTH is an 84 amino acid peptide hormone that is secreted from the chief epithelial cells 
of parathyroid glands and has a plasma half-life of 2–4 minutes. The N-terminate 
fragment (1-34) of the PTH molecule acts through type 1 PTH/PTHrP receptors and is 
the biologically active domain 
22
. PTH plays a critical role in maintaining an adequate 
calcium-phosphorus homeostasis through its impact on bones and kidneys. Calcium is 
the principal regulator of parathyroid glandular activity, through the CaSR on the 
surface of parathyroid cells. The rate of secretion of PTH is inversely dependent on the 
concentration of extracellular ionized calcium (Ca++). The biological actions of PTH, 
Figure 1, include increased bone turnover and release of calcium and phosphate from 
bone; stimulation of calcium resorption and decreased phosphate reabsorption from the 
renal tubules; and increased intestinal absorption of calcium by up-regulation of 1-
alphahydroxylase, the enzyme that converts 25-hydroxyvitamin D (25-OH-D) into its 
active form 1,25 dihydroxyvitamin D (1,25(OH)2D) in proximal renal tubules 
23, 24
. A 
small increase in the extracellular Ca++ level leads to activation of the CaSR, which 
inhibits PTH secretion; conversely, a decrease in the Ca++ level deactivates the 
receptor complex and stimulates PTH secretion.  
 
Serum PTH is routinely analyzed with a two-site antibody immunoradiometric assay 
(IRMA), which recognizes the complete intact PTH (1-84) molecule
 
and incorporates 
two different antibodies that bind to unique
 
sites on the PTH molecule and have 
excellent specificity and sensitivity 
25
.   
 
1.4 CALCIUM 
Calcium is an essential ion in the human body; precise control of the extracellular 
calcium level is necessary to ensure optimum function of essential physiological 
processes. Most of the calcium in the body is stored in the skeleton, which serves as a 
reservoir. In plasma, normal calcium concentrations are maintained by calciotropic 
hormones, in particular PTH and the active form of Vitamin D, 1,25(OH)2D, Figure 1. 
Normal levels of total calcium range from 2.15 to 2.50 mmol/L. Of the total amount, 
50% is free Ca++, 10% is combined with various anions (including bicarbonate, citrate, 
phosphate, lactate and sulphate) and the remaining 40% is bound to serum proteins, 
mainly albumin 
26
. Free Ca++ is the physiologically important component of total 
calcium. In plasma, the Ca++ concentration is normally maintained within a narrow 
range (1.15–1.33 mmol/L).  
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Figure 1. Calcium homeostasis. PTH increases Ca++ resorption and decreases phosphate reabsorption 
in kidney, increases activation of vitamin D in kidney and stimulates bone turnover and release of 
calcium and phosphate from bone. 1,25(OH)2D enhances absorption of calcium and phosphate in 
intestine and stimulates bone resorption. 
 
1.5 VITAMIN D 
The major supplies of vitamin D3 come from exposure to sunlight and dietary uptake. 
Vitamin D3 is converted in the skin from its precursor 7-dehydrocholesterol by 
ultraviolet light. Two sequential hydroxylations of vitamin D3, first in the liver to 25-
OH-D and then in the kidney, convert it into its biologically active form 1,25(OH)2D 
27
. By binding to vitamin D receptors, 1,25(OH)2D increases the absorption of calcium 
and phosphate in the intestines, stimulates bone resorption and reduces serum PTH 
levels by decreasing parathyroid gland activity and indirectly by increasing serum 
calcium, Figure 1. A low level of 1,25(OH)2D results in a transient decrease in serum 
calcium and a compensatory rise in PTH levels; it is one of the causes of secondary 
hyperparathyroidism 
28
. The level of 25-OH-D seems to be the best indicator of vitamin 
D status. 25-OH-D is more stable than the active form; its circulating level in serum is 
roughly 500–1000 x that of the active form and it correlates well with the biological 
effects of vitamin D 
27
. 
 
PTH 
1,25(OH)2D 
↑ bone turnover 
release of Ca++ and 
Phosphate from bones 
 
 
Homeostasis: 
Serum Ca++  
(1.15-1.33 mmol/L) 
 
↑ Ca++  
↑ Phosphate    
uptake in 
intestines 
↑Ca++ and ↓Phosphate 
uptake in kidneys 
25-OH-D → 1,25(OH)2D 
 
 
 
 
↑ Ca++  
↑ Phosphate levels 
 
 Stimulation: 
↓ Ca++ and ↓ Phosphate  
Down regulation:    
↑ Ca++ and ↑ 1,25(OH)2D 
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1.6 PTH AND THE CARDIOVASCULAR SYSTEM 
Besides the target organs, bone and kidney, PTH affects a wide variety of other organ 
systems, including the CV system. PTH has positive inotropic and chronotropic effects 
on the heart 
29, 30
. PTH activates protein kinase C of cardiomyocytes and leads to 
hypertrophic growth and re-expression of fetal-type protein in cardiomyocytes. This 
hypertrophic effect of PTH might contribute to left ventricular hypertrophy in patients 
with hyperparathyroidism 
31-33
.  
 
The link between PTH and vascular tone is complex. PTH has been associated with 
both hypo- and hypertensive effects. While short-term infusion of PTH may induce 
vasodilation and hypotension, long-term infusion results in elevated blood pressure 
(BP) and hypercalcemia 
34, 35
. Several mechanisms have been suggested to explain 
PTH’s vasoactive effects. PTH has a direct vasodilatory effect on the vascular smooth 
muscle cell: through binding to the PTH receptor, the level of cAMP increases and this 
reduces the intracellular influx of calcium and leads to vasodilation 
36
. On the other 
hand, PTH might increase the intracellular influx of calcium into the endothelial cells 
37
. PTH also has an indirect action on the vasculature: through changes in cytokines and 
hormones, augmented renin activity and plasma calcium level, which alters the BP 
38-40
.  
 
PTH has been associated with several parameters involved in the metabolic syndrome, 
such as insulin resistance, high BP, BMI and dyslipidemia, all of which are important 
risk factors for CV diseases 
41
. 
 
1.7 CALCIUM AND THE CARDIOVASCULAR SYSTEM 
Calcium is a crucial signal molecule in the CV system and plays an important role in 
many physiological processes. Ca++ acts as a second messenger via changes in 
intracellular Ca++ levels mediated by the actions of calcium channels, and as first 
messenger through a G-protein-coupled CaSR 
42, 43
. Calcium appears to interact with 
the CV system on several levels, by an increase in vascular resistance mediated via a 
direct effect on vascular smooth muscle as well as indirectly by increments in blood 
levels of various vasopressive substances 
44
. Experimentally induced acute 
hypercalcemia has increased the BP 
40, 45
. In a long-term follow-up study on more than 
30,000 individuals, high serum calcium levels were associated with increased mortality, 
mainly from CV diseases 
46
. In population-based studies, even a calcium level that is 
high up in the normal range and without a diagnosis of PHPT has been recognized as a 
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prospective risk factor for myocardial infarction and carotid plaque thickness, 
suggesting a role of extracellular calcium levels in the atherosclerotic process 
47, 48
.  
 
1.8 CARDIOVASCULAR MANIFESTATIONS IN PHPT 
 
1.8.1 Mortality 
The increased mortality in patients with moderate to severe PHPT is well confirmed in 
several European studies 
6, 49-51
. Malignancy and CV disorders were the major causes of 
death in PHPT patients 
6, 8, 52
. The higher mortality rate persists long after surgical cure 
but decreases with time after PTX 
6, 53
. However, the increased mortality has not been 
confirmed in North American studies 
54, 55
. One explanation can be a milder disease in 
North American patients, who had a lower serum calcium level and fewer symptoms 
than the European patients. This hypothesis was confirmed by Nilsson et al., who 
analyzed mortality over a 30-year period in 10,995 patients who underwent PTX. They 
observed an increased CV mortality which remained over 15 years after PTX, but the 
risk of death in CV diseases, except for stroke, normalized in patients enrolled later in 
the study 
7
. Preoperative PTH, calcium levels and adenoma weight have all been 
reported to correlate to mortality risk 
47, 54, 56, 57
. An elevated serum PTH level has been 
shown to be an independent predictor of impaired long-term survival in an unselected 
aged population 
58, 59
. The decreased mortality shown in the majority of recent studies 
seems to be connected with milder biochemical disturbances but it could also be due to 
earlier diagnoses and interventions or recent advances in therapy for CV diseases 
9
. A 
study with a cohort of untreated patients with mild PHPT found an increased mortality 
and morbidity from several conditions, including CV disease, cancer, diabetes and 
hypertension 
60
. Mortality data in mild PHPT are still limited and future studies are 
needed to confirm these findings.   
 
1.8.2 Cardiac structure and function 
Cardiac structure and function in symptomatic PHPT patients have been extensively 
studied and numerous abnormalities, such as left ventricular hypertrophy (LVH), 
diastolic dysfunction and cardiac conduction abnormalities, have been reported 
61
. Both 
calcium and PTH have been implicated in the development of cardiac diseases 
47, 62
. A 
higher prevalence of myocardial and valvular calcification has been reported in PHPT 
patients with marked hypercalcemia 
33, 63
.   
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LVH, a strong predictor of future CV death, has been reported in both hypertensive and 
normotensive patients with PHPT 
32, 33, 64
. It has been suggested that LVH in PHPT is 
independent of hypertension and is associated with PTH level 
32, 65
. The hypertrophic 
action of PTH on cardiomyocytes, in combination with an increased left ventricular 
afterload due to increased arterial stiffness and central arterial pressure in PHPT, may 
explain the mechanism behind LVH in PHPT patients 
31, 66, 67
. The reversibility of LVH 
after PTX in some studies further supports a coupling between disease-related 
biochemical disturbances and LVH 
32, 33
.   
 
Diastolic dysfunction is associated with a marked increase in all-cause mortality and is 
frequently reported in patients with PHPT, with varying reversibility after PTX 
65, 68-72
. 
A decreased E/A ratio, a Doppler-derived (E, early) and (A, atrial contraction) ratio of 
transmitral peak flow velocity, prolonged isovolumic relaxation time (IVRT) and 
deceleration time (DT) are all variables which may indicate impaired left ventricular 
relaxation and diastolic dysfunction. A reduced E/A ratio, an independent indicator of 
increased all-cause mortality as well as CV mortality, has been shown in PHPT 
68, 69, 73, 
74
. Increased IVRT, indicating diastolic filling impairment, have also been found in 
PHPT 
68, 70, 71
. The interpretation of some of the data is hampered by the presence of 
confounding risk factors; further studies with patients with mild PHPT without other 
CV risk factors are required to confirm these findings. 
 
1.8.3 Vascular structure and function 
Increased carotid intima media thickness (IMT), an early predictor of systemic 
atherosclerosis, is associated with coronary and cerebrovascular events 
75
. Increased 
carotid IMT has been found in patients with severe but not mild PHPT 
76-80
.  
 
Vascular endothelium plays an important role in the biology of the arterial wall through 
the release of vasoactive and trophic factors. Endothelial dysfunction is the initial step 
in the pathogenesis of atherosclerosis and plays a key role in the pathophysiology of 
CV diseases 
81
. Endothelial function has been studied in a few PHPT studies with 
somewhat contradictory results 
79, 82-84
. The majority of the studies used flow-mediated 
vasodilatation of the brachial artery for the evaluation of endothelial function and found 
an impairment of endothelial dependent vasodilation (EDV) in patients with PHPT 
compared to healthy controls which normalized after PTX 
82, 83
. However, this finding 
was not confirmed in another study 
84
. Nilsson et al. evaluated endothelial function by 
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the invasive forearm method and showed a lower endothelial function index (EFI) in 
PHPT patients compared to controls. The EFI correlated inversely to the level of 
calcium and increased after PTX. The same group also reported a dose-related 
impairment in endothelial vasodilatory function during acute hypercalcemia in healthy 
subjects 
40
.  
 
The augmentation index (AI%), an indirect measure of arterial stiffness and endothelial 
function, is an independent predictor of CV mortality. An increased AI% has been 
reported in patients with PHPT 
66, 67
. The presence of PHPT was a stronger predictor of 
elevated AI% than other factors, such as age, gender, smoking, hypertension, 
hyperlipidemia and diabetes mellitus and the increase in AI% was associated with 
evidence of more active parathyroid disease 
66
. These findings indicate a causal link 
between endothelial dysfunction and PHPT.  
 
1.8.4 Hypertension 
Hypertension, a major risk factor for CV morbidity and mortality, is frequently seen in 
association with PHPT even among those with mild disease 
85, 86
. The link between 
PTH and hypertension has been confirmed in several studies, both in PHPT and in 
epidemiological trials 
87-89
. Elevated levels of PTH have been demonstrated in patients 
with essential hypertension 
89, 90
. The mechanisms underlying hypertension in sporadic 
PHPT are not clearly understood. Suggested explanations for the hyperparathyroid 
hypertension include increased total peripheral resistance due to an exaggerated CV 
response to vasoactive hormones and/or abnormalities in the renin-angiotensin-
aldosteron axis 
38
 and an abnormal vasodilatory response 
79, 82
. The effect of PTX on 
BP has been studied, with contradictory results. While some studies have reported a 
decrease in BP after surgical cure 
69, 91, 92
, others have shown no effect 
88, 93
. Adequate 
BP lowering treatment makes a major contribution to reducing the risk of CV events 
94
. 
Long duration of hypertensive and hyperparathyroid conditions may cause irreversible 
changes in the vasculature, which may explain why the majority of studies indicate that 
hypertension is not reversible after surgical cure. For this reason, the presence of 
hypertension in patients with PHPT is currently not an indication for PTX 
9
. 
 
1.9 VITAMIN D AND PHPT 
Vitamin D deficiency has been identified as a risk factor for cancer mortality, CV 
diseases and diabetes, together with other components of the metabolic syndrome 
95, 96
. 
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Values of 25-OH-D below 50 nmol/L are considered to represent vitamin D deficiency 
and values between 50–75 nmol/L are considered to represent vitamin D insufficiency 
27
. Several studies have shown that vitamin D deficiency occurs more frequently in 
patients with PHPT compared with the general population, and is usually associated 
with an aggravated form of the disease 
97, 98
. In areas with endemic vitamin D 
deficiency, coexistent PHPT has been associated with higher preoperative PTH values 
and larger adenomas 
97, 99
. The exact causal link between vitamin D deficiency and 
PHPT is not clear. One of several possible explanations could be that chronic vitamin D 
deficiency stimulates parathyroid glands and leads to hyperplasia and adenoma growth 
100, 101
. Other possible mechanisms could be that the increased 1,25(OH)2D levels in 
PHPT patients, due to enhanced renal conversion of 25-OH-D to 1,25(OH)2D in 
kidneys, may inhibit the dermal production of vitamin D3 and 25-OH-D in the liver. 
There are also data suggesting that the half-life of 25-OH-D is shortened in PHPT due 
to increased hepatic inactivation 
102, 103
.  
 
The guidelines from an expert panel in 2009 state that the level of 25-OH-D should be 
assessed in all patients suspected of having PHPT, and that vitamin D deficiency should 
be corrected to achieve a serum level of 25-OH-D above 50 nmol/L 
104
. 
 
1.10 LIPOPROTEIN DISTURBANCES IN PHPT 
The association between increased low density lipoprotein (LDL)-cholesterol, 
triglycerides and decreased high density lipoprotein (HDL)-cholesterol on the one hand 
and enhanced risk of CV mortality and morbidity on the other is well established 
105
. 
Apolipoprotein B (apo-B) and apolipoprotein A1 (apo-A1) are thought to be better 
predictors of acute myocardial infarction than total cholesterol and LDL-cholesterol 
106
. 
PHPT has been associated with dyslipidemia, such as increased cholesterol, 
triglycerides (TG) and decreased level of HDL-cholesterol 
67, 107
. Dyslipidemia in mild 
PHPT has been reported in a few studies, with an improvement after PTX 
5, 108
. 
 
1.11 CARDIOVASCULAR RISK MARKERS 
Plasma levels of several haemostatic and inflammatory variables have been associated 
with CV events in numerous prospective epidemiological trials and in a few PHPT 
cohorts 
109-113
. Higher levels of platelet count, D-Dimer and coagulation factors VII and 
X activity have been observed in PHPT patients compared to controls; the potential 
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hypercoagulability in PHPT patients may augment the risk of atherosclerotic and 
atherothrombotic complications 
111
.  
 
Inflammation plays an important roll in the atherosclerotic process. Inflammatory 
biomarkers such as high sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6) 
have been identified as predictors of CV events 
114, 115
. Both normal and increased 
levels of IL-6 or/and CRP have been shown in PHPT studies, with varying 
normalization after PTX 
116-118
. The discrepancy between the results may partly be 
explained by differences between the studies in disease severity and CV risk factors.   
 
The biochemical marker plasminogen activator inhibitor-1 (PAI-1) is a principal 
inhibitor of fibrinolysis and is associated with CV diseases and diabetes 
119
. An 
elevated PAI-1 level can predict future risk of myocardial infarction and diabetes 
120, 
121
. A reduced fibrinolytic capacity due to increased plasma levels of PAI-1 has been 
suggested to play an important role in the pathogenesis of CV diseases, particularly in 
patients with hypertriglyceridemia 
122
. An increased PAI-1 level has been reported in 
patients with PHPT and may be involved in the pathogenesis of CV diseases in these 
patients 
123, 124
.  
 
The large glycoprotein von Willebrand factor (VWF) is mainly produced by vascular 
endothelial cells and plays an important role in platelet adhesion and aggregation. An 
increased level of VWF has been associated with the risk of coronary heart disease and 
acute ischemic stroke 
125, 126
. The role of VWF in PHPT patients has been studied in a 
few studies, none of which found an abnormal VWF level 
111, 116
.  
 
Insulin-like growth factor 1 (IGF-1) is structurally and functionally very similar to 
insulin and plays an important role in the regulation of cell proliferation and 
differentiation. It is synthesized mainly in the liver under the control of growth 
hormone. IGF-1 is expressed in most tissues and is implicated in the pathogenesis of 
insulin resistance and CV diseases. Low IGF-1 levels are associated with the presence 
of insulin resistance, metabolic syndrome and CV diseases 
127
.  
 
The amino acid homocysteine is emerging as a distinct marker of the risk of CV 
disease. Elevated levels of homocysteine have been reported as an independent 
predictor of ischemic heart disease and stroke in healthy populations 
128
.  
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1.12 TREATMENT OF PRIMARY HYPERPARATHYROIDISM 
The only cure for PHPT is surgical removal of the abnormal parathyroid tissue. The 
standard operation is a full neck exploration with identification of all glands. Thanks to 
improved techniques for preoperative localisation of parathyroid adenoma (ultrasound 
and scintigraphy) and methods for peroperative PTH assays, many patients are now 
operated with a minimally invasive approach 
129
. Both the traditional and the minimal 
invasive procedures have a success rate of > 95% and very low morbidity when 
performed by experienced endocrine surgeons 
130
.  
 
The long-term effects of PTX in symptomatic patients have been evaluated in many 
epidemiological trials. An improvement in bone mineral density (BMD), a reduced 
fracture risk, positive effects on cognitive function and kidney stone incidence and 
decreased CV mortality and morbidity have been demonstrated after PTX 
33, 53, 131-133
. 
While it is generally agreed that PHPT patients with end-organ signs and symptoms 
should be offered PTX, the indication for surgery in asymptomatic patients is still 
debated. The current criteria for surgery according to the third international guidelines 
for asymptomatic PHPT are: age < 50 years, serum calcium levels > 0.25 mmol/L 
above the upper limit of normal, creatinine clearance < 60 ml/min and BMD detected 
T-score < −2.5 at any site and/or previous fracture fragility 104. Recent data show that 
even asymptomatic mild PHPT patients have subtle neurocognitive symptoms and a 
declining BMD over time that improve after PTX 
9
. Surgery is recommended for 
asymptomatic PHPT patients who meet any of the guidelines criteria and is always an 
option in those who do not fulfil the criteria when medical surveillance is not possible. 
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2 AIMS OF THE THESIS 
 
Our knowledge of CV manifestations in PHPT is mainly based on data from cohorts 
that include patients with varying disease severity and pre-existing CV risk, which may 
confound the results and explain the discrepant findings in the literature. The main 
objective of this thesis was to evaluate the CV function in a selected group of patients 
with mild PHPT without known CV diseases or risk factors.  
 
 To investigate the acute effect of an elevated PTH level on endothelial 
vasodilatory function in young healthy subjects (study I).  
 
 To evaluate cardiac structure and function by echocardiography and Doppler 
tissue imaging (DTI) in patients with mild PHPT and the effect of PTX (study 
II).  
 
 To study the vascular structure, function and intima-media thickness in the 
carotid and radial arteries and the echogenecity of the intima-media complex in 
the carotid artery in mild PHPT and the effect of PTX (study III). 
 
 To analyze the prevalence of vitamin D deficiency and other biochemical 
markers associated with an increased CV risk in mild PHPT and the effect of 
PTX (study IV). 
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3 MATERIAL AND METHODS 
 
 
3.1 SUBJECTS AND STUDY DESIGN 
 
3.1.1 Study I 
The study participants were recruited from the responders to a local newspaper 
advertisement in Uppsala. We started with a pilot study with 3 healthy volunteers (1 
man and 2 women), aged 22–25 years, to determine an appropriate rate of intra-arterial 
infusion of PTH to achieve a PTH level above the upper normal range (6.9 pmol/L). 
Thereafter, 10 healthy volunteers (5 men and 5 women, aged 21–28 years) were 
included in the study. Female subjects underwent a pregnancy test before inclusion. 
None of the subjects were taking any medication, had a history of any disease known to 
affect the CV system or used nicotine regularly. Each subject gave written consent to 
participate in the study, which was approved by the Ethics Committee of Uppsala 
University. 
 
3.1.2 Studies II–IV 
The patient population was consecutively recruited from the referrals for parathyroid 
surgery due to PHPT at the Karolinska University Hospital in Stockholm, Sweden, 
between January 2006 and November 2008. During the study period, a total of 410 
PHPT patients (319 women) were treated with PTX at the clinic. The following 
inclusion criteria were used: patients with PHPT being considered for PTX, no history 
of CV diseases or any other disease known to affect the CV system, no medication 
affecting the CV system, no diabetes mellitus or renal diseases, no arterial hypertension 
(defined as systolic blood pressure (SBP) > 140 mmHg and diastolic blood pressure 
(DBP) > 90 mmHg), body mass index (BMI) < 28 and age > 18 and < 70 years. Fifty-
three patients met the inclusion criteria and agreed to participate in the study. After 
inclusion, two patients were dropped from the study: a woman who regretted her 
decision to undergo PTX and a man who was diagnosed with familial hypocalciuric 
hypercalcemia by specific mutation analysis after parathyroid exploration with the 
finding of normal parathyroids. None of the subjects were current smokers at inclusion. 
A majority of the patients had no overt symptoms or signs associated with PHPT; 
except for a history of kidney stone disease (n=9) and BMD below −2.5 at any site 
(n=6). Mild PHPT was defined as plasma calcium less than 2.75 mmol/L and/or the 
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absence of overt symptoms related to hypercalcemia. The healthy control group 
(matched by age, gender and geographic area) was randomly selected from the 
population registry of the city of Stockholm. These subjects received a mailed 
invitation to participate in the study and were recruited if they fulfilled the inclusion 
criteria described above except that they had normal P-calcium and normal P-PTH. 
Two controls were replaced before entering the study, one because of a high P-PTH 
level, the other because of hypertension. Finally, 51 patients and 51 controls (16 men 
and 35 women) were included in the study.  
 
Blood samples were collected for biochemical analyses and the CV system was 
evaluated by echocardiography, DTI, carotid artery ultrasound, high resolution 
ultrasound of the radial artery and pulse-wave analysis at baseline. Fifty patients were 
re-examined after a mean follow-up time of 15±4 months (range 7 to 28 months) after 
PTX. One woman only participated in the blood analyses at follow-up. Two patients 
were on cholesterol-lowering treatment (atorvastatin) and were excluded from the 
analyses in studies III–IV along with their matched controls. Another patient and his 
matched control were excluded in study III due to carotid image storage failure. Each 
subject gave written consent to participate in the study, which was approved by the 
Local Ethics Committee of Stockholm. 
 
3.2 METHODS  
 
3.2.1 Forearm blood flow measurement (study I) 
Forearm venous occlusion plethysmography is a well-established method for 
measuring forearm blood flow (FBF) 
134, 135
.
 
The method is based on measurement of 
the increase in forearm volume after the venous return has been occluded by placing an 
inflated cuff (at a pressure of 30–40 mm Hg for 7 seconds) around the upper arm. At 
this pressure, venous occlusion occurs without any modification of the arterial inflow. 
The change in upper arm circumference is recorded by a mercury-in-silastic strain 
gauge placed around the forearm and connected to a calibrated plethysmograph. FBF is 
expressed graphically and is calculated (slope of the curve) as the mean of at least five 
consecutive recordings Figure 2. With this method, cannulation of the brachial artery 
can be used to infuse vasoactive drugs in one arm without causing any alterations in 
systemic haemodynamics or in blood flow in the contralateral arm.
 
FBF is then 
measured in both forearms and the contralateral arm serves as a control. Arterial 
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infusion of metacholine (MCh), a muscarinic receptor agonist that causes an 
endothelium-mediated vasodilator response, is used for evaluation of endothelium-
dependent vasodilation (EDV). Arterial infusion of sodium nitroprusside (SNP), which 
directly affects the vascular smooth muscle cells, is used for evaluation of endothelium-
independent vasodilation (EIDV). The endothelial function index is calculated as the 
ratio of FBF during the highest dose of MCh, 4 µg/min (EDV), to the highest dose of 
SNP, 10 µg/min (EIDV). This index expresses the contribution of endothelial nitric 
oxide (NO) release to the vasodilatory process. Evaluation of the reproducibility of 
measurements of EDV and EIDV using this technique has shown a variation of 5–8% 
in the short- (2 h) and long-term (3 weeks) perspectives 
135
. A previous study 
performed in the same laboratory by one of the authors showed that local intra-arterial 
infusion of saline did not significantly change either baseline FBF or the responses to 
MCh and SNP and the endothelial function index in the active arm 
136
. 
 
 
 
Figure 2. Measurement of forearm blood flow using venous occlusion plethysmography. 
 
3.2.2 Experimental procedure (study I) 
The subjects were investigated after an overnight fast in the supine position in a room 
maintained at a constant temperature. An arterial cannula was inserted in the brachial 
artery (active arm) for administration of the study drugs (PTH, SNP and MCh). The 
contralateral arm was used as control. The experimental procedure is shown 
schematically in Figure 3. The levels of PTH and Ca++ were analyzed in the active arm 
in all subjects and in the control arm as well in 4 subjects (for evaluation of systemic 
influence) at baseline and after 30 min of PTH infusion. FBF was measured at baseline 
before drug infusions in both arms. Thereafter, vasodilation in the active arm was 
achieved by infusion of one of the vasodilatory drugs (SNP or MCh) for 5 min. The 
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drugs were given in a random order at a maximum rate of 1 ml/min. The infused 
dosages were 2 and 4 µg/min for MCh and 5 and 10 µg/min for SNP. FBF was 
recorded in both arms at the end of the infusion. This procedure was repeated with the 
other vasodilatory drug after 20 min of washout time. The PTH infusion was started 
after these baseline measurements. After 30 min of PTH infusion, the blood flow 
measurements were repeated as described above. 
 
 
Resting 
FBF
MCh SNP
PTH
Infusion
Resting
FBF 
MCh SNP
Blood test
Ca++, PTH
Blood test
Ca++, PTH
Start After 30 min End
 
Figure 3. Experimental procedure, study I. 
 
3.2.3 Intra-arterial infusion of PTH (study I) 
We used Preotact® (Nycomed), a full-length parathyroid hormone (PTH 1-84), diluted 
with saline in three steps to 0.2µg/ml. In a pilot study with 3 volunteers, we determined 
the intra-arterial infusion rate that was needed to attain a PTH level above the upper 
normal range (6.9 pmol/L) in the active arm without any systemic effect. Guided by the 
results of the pilot study, a dose rate of 70 ml/h during 30 minutes was chosen for the 
PTH infusion.  
 
3.2.4 Blood pressure, BMI and GFR (studies II–IV) 
BP was measured in both arms after at least 30 minutes of rest, using an appropriately 
sized cuff and automatic monitor (Digital Automatic Blood Pressure Monitor, Omron 
M7). The mean values of systolic and diastolic BP in the two arms were calculated and 
heart rate was noted. BMI was calculated by dividing weight (kg) by the square of 
height (m). Renal function was estimated by calculating the glomerular filtration rate 
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(GFR) according to Cockroft-Gault’s formula: GFR= (140 − age in yr) x (weight in 
kg/P-creatinine) x (1.23 in men, 1.04 in women). 
 
3.2.5 Body surface area (studies II and III) 
Body surface area (BSA) was calculated with the formula: BSA= (0.0001) × (71.84) × 
(weight)
0.425 
× (height)
0.725 
where weight was measured in kilograms and height in 
centimetres. 
 
3.2.6 Echocardiography (study II) 
All examinations were performed by one experienced echocardiographer, using an 
ultrasound scanner Vivid 7 (General Electric, Horten, Norway) equipped with DTI 
capabilities. The patients were placed in the left lateral recumbent position and the two-
dimensional, M-mode and Doppler echocardiography was performed in accordance 
with the guidelines of the American Society of Echocardiography 
137
. All images were 
stored digitally on an ultrasound database Echopac. Standard echocardiographic 
measurements included right ventricular end-diastolic diameter (RVDd), left atrial end-
systolic area, left ventricular (LV) end-diastolic (LVDd) and end-systolic diameter 
(LVDs), end-diastolic interventricular septum thickness (IVSd) and left ventricular 
posterior wall thickness (PWTd). The fractional shortening (FS %), ejection fraction 
(EF %) and atrioventricular plane (AV-Plane) displacement were calculated from M-
mode recordings. LV mass was calculated with the formula: LVM (grams) = 0.8 [1.04 
[(LVDd + IVSd + PWTd)
3 
- (LVDd)
3
]] + 0.6 g. The LV mass was divided by BSA to 
calculate the LV mass index (LVMI). The cut-off point for LV hypertrophy (LVH) 
using the LVM/BSA ratio was 150g/m² for males and 120g/m² for females 
138
. 
Transmitral inflow and pulmonary venous flow velocities were obtained with pulsed 
wave Doppler. The velocities of early transmitral diastolic flow (E) and flow velocity 
during atrial contraction (A), its ratio (E/A), deceleration time (DT) and isovolumic 
relaxation time (IVRT) were measured, Figure 4.  
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Figure 4. Measurement of transmitral diastolic flow velocities by pulsed-Doppler echocardiography. E= 
early transmitral diastolic flow, A= flow velocity during atrial contraction and DT= deceleration time. 
 
3.2.7 Doppler tissue imaging (study II) 
Pulsed DTI was recorded in the apical four-chamber view at three sites: the tricuspid 
annulus for the right ventricle and in the septal, Figure 5, and lateral parts of the mitral 
annulus for the left ventricle. A 3-mm sampling volume was used. Peak systolic (S´), 
early diastolic (E´) and late diastolic (A´) velocities recorded by DTI were measured. 
E´/A´ and E/ E´ for the septal and the lateral part of the mitral annulus were calculated.  
 
 
 
Figure 5. Measurement of peak myocardial velocities in the septal part of the mitral annulus by DTI. S´- 
peak systolic, E´- early diastolic and A´- late diastolic velocities.  
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3.2.8 Carotid artery ultrasound (study III) 
Two dimensional images of the common carotid artery (CCA) were obtained with an 8 
MHz transducer, 7L (Vivid 7, General Electric, Horten, Norway). All subjects were 
examined in supine position by one experienced sonographer. The CCA was evaluated 1–
2 cm proximal to the bulb. Diastolic images at the time of the electrocardiographic R-
wave were stored digitally on EchoPAC, Image Vault 5.0 system. For detection of intima 
media thickness (IMTcca) and intima media grey scale median (IM-GSM), three digitized 
images were imported to the automated software, Artery Measurement Software (AMS) 
139, 140
.  
 
AMS was developed in collaboration between the Department of Signals and Systems at 
Chalmers University of Technology and the Physiology Group at the Wallenberg 
Laboratory, Gothenburg University, Gothenburg, Sweden. A region of interest (ROI) was 
manually placed at the beginning of the bulb, and IMTcca and lumen diameter (LDcca) were 
calculated from around 100 discrete measurements through a 10 mm long segment, Figure 
6. The borders of the IMTcca and LDcca were identified automatically by the programme 
and could be manually corrected if necessary. LDcca was measured from the intima-lumen 
interface of the near wall to the lumen-intima interface of the far wall. Intima media 
thickness was defined as the distance from the leading edge of the lumen-intima interface 
to the leading edge of the media-adventitia of the far wall 
141
, Figure 6. IM-GSM was 
calculated from image analyses of pixels in the range of 0 (black) and 255 (white). The 
adventitia was used as the reference for white and the blood as the reference for black. 
 
IMTcca, IM-GSM and LDcca are presented as a mean value from six images, three images 
from left respectively right CCA. Lumen diameter and IMTcca values are shown in mm, 
while IM-GSM is shown as median grey. The image analyses and calculations were 
performed in random order by the same investigator.  
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Figure 6. The IMTcca and IM-GSM are measured in the far wall (red box). The diastolic LDcca is measured 
from the intima-lumen interface of the near wall to the lumen-intima interface of the far wall (white arrow).  
 
3.2.9 High resolution ultrasound of the radial artery (study III) 
A high resolution ultrasound investigation of the radial artery was performed in 43 
patients. The images of the intima media of the radial artery were obtained by high 
resolution ultrasound, using a 55 MHz transducer (Vevo 770, VisualSonics, Toronto, 
Canada). The subjects were examined in supine position. B-mode images were 
recorded from the right radial artery in a longitudinal projection. All cine loops were 
stored on an external disk and measured off-line using VisualSonics software. The 
thickness of the radial artery intima media (IMTrad) and lumen diameter (LDrad) were 
measured according to the leading edge principle 
141
. Three sets of measurements 
were performed from each of three representative images. The IMTrad of the far wall 
is presented as a mean value from 9 measurements corresponding to end-diastole, the 
smallest lumen diameter. The IMTrad was defined as the distance from the lumen-
intima interface to the media-adventitia interface, Figure 7. Diastolic LDrad was 
measured from the M-mode image, defined by the distance between the intima-lumen 
interface of the near wall and the lumen-intima interface of the far wall. LDrad is 
presented as a mean value taken from three representative beats. 
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Figure 7. The IMTrad  in the right radial artery was measured from the lumen-intima interface to the 
media-adventitia interface. 
 
3.2.10 Pulse-wave analysis (study III) 
The subjects were studied in supine position after resting for 60 minutes. Pulse-wave 
analysis (PWA) was performed noninvasively using SphygmoCor equipment 
connected to a computer with SphygmoCor 2000 software (version 7.01, AtCor 
Medical, Sydney, Australia). PWA was registered with a single high-fidelity tonometer 
gently pressed against the artery (SPT-301B, Millar Instruments, Houston, Texas, 
USA). The recorded artery waves were collected and processed by the system software. 
To assess AI%, the radial artery wave was recorded. The corresponding aortic pressure 
waveform was generated from an averaged radial artery waveform using a validated 
transfer factor 
142, 143
, Figure 8. AI% is defined as the difference between the first and 
the second peaks of the central aortic waveform, expressed as a percentage of the pulse 
pressure 
144
. AI% is presented as a mean value taken from two or more optimal 
recordings. The radial wave was calibrated to the brachial systolic and diastolic BP, 
using an automatic monitor (Digital Automatic Blood Pressure Monitor, Omron M7). 
All measurements were performed by the same investigator. 
 
 
Figure 8. Pulse- wave analysis - the recorded radial waveform and the derived aortic pressure 
waveform.   
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3.3 IMAGE ANALYSES 
 
3.3.1 Study II 
All variables describing cardiac dimensions and structure were analyzed off-line by one 
observer unaware of the subject’s status. The remaining Doppler-derived variables 
were analyzed by another observer. All measurements were averaged from at least 3 
heart beats. To assess the measurement variability, the two observers re-measured 20 
randomly selected echocardiographic and DTI examinations. The coefficient of 
variation was calculated for variables for determination of inter- and intra-observer 
variability. Coefficient of variation was calculated as the mean percent error, defined as 
the standard deviation of the absolute differences between the two sets of 
measurements, divided by the mean of two measurements. 
 
The coefficient of variation for DTI assessed myocardial velocities was 3–4% for inter-
observer and 2–3% for intra-observer analyses. The variability for transmitral flow 
velocity was: inter-observer coefficient of variation 2–4 %, intra-observer coefficient of 
variation 1–2%. The coefficient of variation for M-mode atrioventricular plane 
displacement was 2–4% for inter-observer and 2–3% for intra-observer analyses. 
 
3.3.2 Study III 
The image analyses and calculations were performed in random order by the same 
sonographer. To assess the intra- and inter-observer variability of IMTcca and IM-GSM 
measurements, two observers re-measured 30 randomly selected subjects. Six images, 
three from each side of CCA, were measured and a mean value was calculated. For 
evaluation of observer variability, the coefficient of variation was calculated as described 
above. Intra- and inter-observer variability in terms of coefficients of variation were for 
IMTcca  2.90% and 3.80%, for LDcca 0.40% and 0.70%, for IM-GSM 2.74% and 3.81%, 
for IMTrad  5.78% and 10.94% and for LDrad 3.16 and 3.56%. 
 
3.4 LABORATORY METHODS 
 
3.4.1 Study I 
Anaerobic venous samples from the active arm were analyzed at baseline and after 
PTH infusion, for Ca++ ( i- STAT 1- Abbott, normal range 1.1–1.3 mmol/L) and intact 
plasma PTH (Immunolite 2500, Diagnostics Product Company LA, CA, USA; intact P-
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PTH, normal range 1.1–6.9 pmol/L). Plasma PTH and Ca++ levels were also analyzed 
in the contralateral arm in 4 subjects to exclude a systemic effect during the infusions. 
3.4.2 Studies II–IV 
Blood samples in patients and controls were drawn in the fasting state in the morning. 
Plasma concentrations of total calcium, alkaline phosphatase (ALP), creatinine, 
glucose, phosphate, hs-CRP and homocysteine, and serum concentrations of total 
cholesterol, triglycerides (TG), apolipoprotein A1 (apo-A1) and apolipoprotein B (apo-
B) were measured using the Synchron LX ® 20 system (Beckman Coulter inc., Brea, 
CA, USA). Serum Ca++ concentrations were analyzed on ABL 800 (Radiometer, 
Copenhagen, Denmark) and plasma concentrations of intact PTH were determined with 
electrochemiluminescence immunoassay on the Modular E system (Roche Diagnostics 
GmbH, Mannheim, Germany). Total serum insulin-like growth factor 1 (IGF-1) was 
analyzed by chemiluminescence immunoassay on DPC Immulite 2000 (Siemens 
Heathcare Diagnostics, Munich, Germany). Serum concentrations of 25-OH-D were 
measured by chemiluminescence on Liason ® (DiaSorin, S.p.A, Italy); values below 50 
nmol/L were considered to represent vitamin D deficiency and values between 50 and 
75 nmol/L, vitamin D insufficiency 
27
. The plasma concentrations of VWF antigen 
were determined with a latex immunoassay on the BCS XP system (Siemens 
Healthcare Diagnostics, Munich, Germany), and the plasma activity of PAI-1 by a 
functional enzymatic ELISA assay (Chromolyze PAI-1) from Medinor (Axis-Shield, 
Dundee, U.K.). In order to minimize inter-assay variation, the pre- and postoperative 
samples of 25-OH-D, VWF antigen and PAI-1, together with the sample from the 
randomized controls, were frozen at –70°C and then analyzed in the same series. All 
the analyses could not be completed in some cases because of technical problems or 
missed blood sample collection. 
 
3.5 STATISTICS 
The sample size for study I was based on earlier similar experimental studies 
40
. The 
sample size for studies II–IV was based on differences and standard deviation (SD) of 
diastolic function from earlier studies to guarantee a power level of 80% at a 
confidence level of 95% 
71, 145
. Statistical analysis was performed with the PASW for 
Windows statistical package 18.0 (PASW Inc; Chicago, IL, USA). Data are expressed 
as mean ± SD. Comparisons between the group of patients at baseline and the control 
group were performed with the Mann-Whitney U test for unpaired data. The Wilcoxon 
signed rank sum test was used for intra-individual analyses. Relationships between 
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variables were assessed with Spearman's ρ correlation test. All tests were done two-
tailed and P < 0.05 was considered to be statistically significant. Multivariate linear 
regression and stepwise analyses were used in study III to evaluate relationships and 
adjust for confounders.  
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4 RESULTS 
 
4.1 FBF MEASUREMENT AND BIOCHEMICAL DATA (STUDY I) 
Biochemical data, resting FBF, EDV and EIDV values in the active arm for all study 
subjects are presented in Table 1. Ca++ and PTH values were normal in all subjects at 
baseline. After 30 minutes of PTH infusion, the PTH level increased significantly in the 
active arm, while Ca++ remained unchanged, Table 1. Resting FBF, EDV and EIDV 
did not change during PTH infusion, Table 1. EDV (MCh 4 µg/min) correlated 
inversely to the Ca++ level in the active arm (baseline r= –0.75; p< 0.05, after PTH 
infusion, r= –0.68; p<0.05).  
 
Table 1. Forearm blood flow and biochemical data in the active arm for all subjects at 
baseline and after parathyroid hormone infusion. 
 
Variables Baseline 
(n=10) 
PTH-Infusion 
(n=10) 
P 
Ca++ (1.1–1.3 mmol/L) 1.26 0.02 1.25 0.04 ns 
PTH (1.1–6.9 pmol/L) 3.6 1.2 13.8 4.0 p< 0.01 
Resting FBF 
(ml/min/100 ml tissue) 
4.5 1.5 5.0 2.3 ns 
EDV ( MCh, 2 µg/min )  20.0±13.4 21.5±13.0 ns 
EDV ( MCh 4 µg/min)  24.7±13.1 29.1±15.9 ns 
EIDV (SNP 5 µg/min)  16.2±3.5 18.3±8.2 ns 
EIDV (SNP 10 µg/min)  22.2±7.9 24.0±9.7 ns 
Endothelial function index 1.09±0.41 1.25±0.57 ns 
 
Values are shown as mean ± SD. Ca++= ionized calcium, PTH= parathyroid hormone, 
FBF= forearm blood flow, EDV= endothelium-dependent vasodilation, MCh= 
metacholine, EIDV= endothelium-independent vasodilation, SNP= sodium 
nitroprusside. 
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FBF, Ca++ and PTH measured in the control arm remained mainly unchanged during 
the whole experiment, Table 2.  
 
Table 2. Forearm blood flow and biochemical data for all subjects before and after 
parathyroid hormone infusion in the control arm. 
 
Variables Baseline 
(n=10) 
PTH-Infusion 
(n=10) 
P 
Ca++ (1.1–1.3 mmol/L) 1.26 0.02 a 1.28 0.02 a ns 
PTH (1.1–6.9 pmol/L) 3.2 0.86 a 3.5 0.39 a ns 
Resting FBF 
(ml/min/100 ml tissue) 
3.9 1.7
 b
 3.5 1.8 p<0.05 
EDV ( MCh, 2 µg/min )  3.7±1.1 3.1±1.4 ns 
EDV ( MCh 4 µg/min)  3.9±1.7 3.5±1.3 ns 
EIDV (SNP 5 µg/min)  4.3±2.8 3.5±1.8 ns 
EIDV (SNP 10 µg/min)  3.9±2.2 3.6±1.6 ns 
 
a 
n =4, 
b
n=9. Values are shown as mean ± SD. Ca++= ionized calcium, PTH= parathyroid hormone, 
FBF= forearm blood flow, EDV= endothelium-dependent vasodilation, MCh= metacholine, EIDV= 
endothelium-independent vasodilation, SNP= sodium nitroprusside. 
 
 
4.2 CLINICAL AND BIOCHEMICAL DATA (STUDIES II–IV) 
Clinical and biochemical data of patients and controls are given at baseline and after 
PTX in Table 3. Forty-eight patients had a single parathyroid adenoma and 3 patients 
had multiglandular disease. The majority of our patients had no overt symptoms or 
signs associated with PHPT; except for a history of kidney stone disease (n=9) and 
BMD below −2.5 at any site (n=6). The plasma calcium levels were less than 2.75 
mmol/L, in the majority of cases, only 5 patients had plasma calcium levels between 
2.76–2.97 mmol/L at the time of inclusion. Normocalcemia was achieved in 49 of 51 
patients after the first PTX; the other two became normocalcemic after a second 
operation, when a second parathyroid adenoma and an intrathyroidal adenoma, 
respectively, were removed. All patients were normocalcemic at the postoperative 
follow-up one month after PTX (not shown). There were no PTX-related 
complications. The mean total wet weight of the excised abnormal parathyroid tissue 
was 619±837 mg (median 409 mg). The patients were re-examined a mean of 15±4 
months after successful PTX. Plasma intact PTH, plasma calcium and Ca
++
 were 
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significantly higher in patients at baseline compared to healthy controls, while serum 
phosphate levels were significantly lower, Table 3. PTH, calcium and phosphate 
concentrations normalized after PTX and did not differ from controls at the follow-up 
visit, Table 3. Systolic blood pressure (SBP) was significantly higher in the PHPT 
group compared to controls and decreased after PTX, Table 3. SBP correlated to the 
levels of PTH (r=0.26, P<0.01, Figure 9A) and Ca
++ 
(r=0.25, P<0.05, Figure 9B). 
Diastolic blood pressure (DBP) decreased after PTX, Table 3. BMI increased after PTX 
only in female PHPT (23.5±2.7 vs. 24.3±3.3, kg/m
2
, P<0.01), not in men (25.3±3.0 vs. 
25.6±3.7, kg/m
2
, ns). 
 
Table 3. Clinical and biochemical data for healthy controls and for patients with 
primary hyperparathyroidism before and 15±4 months after parathyroidectomy. 
 
Variable Controls PHPT cases P 
 
n=51 
Baseline 
n=51(35♀) 
Follow-up 
n=51(35♀) 
PHPT 
baseline 
vs. 
controls 
PHPT 
baseline 
vs. 
follow-up 
Age (yr.) 55.2±8.9 54.3±8.8 55.6±8.7   
BMI (kg/m
2
)  23.4±2.1 24.1±2.9 24.7±3.2 ns <0.05 
BSA 1.78±0.17 1.83±0.18 1.85±0.18 ns <0.05 
SBP at rest, (mmHg) 119.6±12.6 127.6±17.1 124.6±16.6
a
 <0.05 <0.05 
DBP at rest, (mmHg) 76.1±7.7 80.3±9.6 78.4±8.6
 a
 ns <0.05 
S-Ca++ (mmol/L) 1.25±0.04 1.46±0.07 1.25±0.05 <0.001 <0.001 
P-Calcium (mmol/L) 2.29±0.08 2.62±0.13 2.28±0.08 <0.001 <0.001 
P-Albumin (g/L) 38.4±2.6 39.4±2.5 38.5±2.9 <0.05 <0.05 
P-PTH (ng/L) 44.1±12.4 122.6±43.6 48.8±15.2 <0.001 <0.001 
P-Phosphate (mmol/L) 1.1±0.2 0.84±0.2 1.0±0.2 <0.001 <0.001 
P-Creatinine (µmol/L) 69.7±13.7 67.3±12.6 
a
 69.1±16.6
 b
 ns ns 
P-Glucose (mmol/L) 5.0±0.35 5.0±0.44
 b
 5.0±0.51
 a
 ns ns 
 
a
 n=50, 
b
n=47–49. Values are shown as mean ±SD. BMI= body mass index, BSA= body surface area, 
SBP= systolic blood pressure, DBP= diastolic blood pressure, Ca++= ionized serum calcium, PTH= 
parathyroid hormone. 
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A. 
 
B.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9 A and B.  Systolic blood pressure for the whole group of PHPT patients and the healthy control 
subjects was correlated to the PTH level (r=0.26; P<0.01, A) and the ionized calcium level (r=0.25; 
p<0.05, B). 
 
4.3 ECHOCARDIOGRAPHY (STUDY II) 
There were no differences between the groups in the variables describing cardiac 
dimensions and structure, Table 4. The systolic and diastolic left ventricular functions 
evaluated by Doppler echocardiography were within normal limits and there were no 
differences between the groups at baseline, Table 5. The regional peak systolic 
myocardial velocities (S´) measured with DTI in the base of the right and left ventricles 
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decreased after PTX, Table 5. For variables with a significant change after PTX we also 
tested post-PTX results for possible differences compared to the control group. 
Compared to our age- and gender-matched healthy controls, the PHPT group had 
numerically lower peak systolic velocities after PTX but the difference reached 
statistical significance only in the lateral part of the mitral annulus, Table 5. For 
comparison, previously published normal values for DTI myocardial velocities for right 
and left ventricles are shown in Table 5 
146, 147
. The values are in the same range as in 
our healthy control group.  
 
The peak systolic velocity of the septal part of the mitral annulus correlated 
significantly and positively to the Ca
++
 level (r=0.35, p<0.05) in the PHPT group at 
baseline. IVRT was increased in the male PHPT group compared to the female PHPT 
group and the healthy controls (PHPT males; 97±20, PHPT females; 82±15, controls 
males; 84±13, controls females; 82±17 P<0.05). The E/A ratio was inversely correlated 
to the PTH level (r= −0.33, p<0.01), SBP (r= −0.40, p<0.01) and DBP (r= −0.46, 
p<0.01). 
 
Table 4. Echocardiographic variables for healthy controls and patients with primary 
hyperparathyroidism before and 15±4 months after parathyroidectomy. 
 
Variable 
 
Controls PHPT cases P 
 
n=51 
Baseline 
n=51(35♀) 
Follow-up 
n=50(34♀) 
PHPT 
baseline 
vs. 
controls 
PHPT 
baseline 
vs. 
follow-up 
HR, at rest (per min) 61±9 62±10 60±9 ns ns 
RVDd (cm) 2.77±0.41 2.70±0.36 2.77±0.36 ns ns 
LVDd (cm) 4.89±0.41 4.94±0.40 4.94±0.40 ns ns 
LVDs (cm) 3.12±0.40 3.12±0.37 3.15±0.33 ns ns 
Left atrial area (cm²) 19.20±2.80 19.91±3.08 19.94±2.55 ns ns 
IVS (cm)  0.91±0.13 0.94±0.16 0.96±0.15 ns ns 
PWT (cm) 0.86±0.16 0.88±0.11 0.86±0.13 ns ns 
LVMI (g/m²)   Males  
                        Females  
93.7±11.7 
80.6±20.1 
99.3±18.4 
81.8±12.3 
98.4±16.0 
80.4±14.8 
ns 
ns 
ns 
ns 
 
Values are shown as mean ±SD. HR= heart rate, RVDd= right ventricular end-diastolic diameter, LVDd= left 
ventricular end-diastolic diameter, LVDs= left ventricular end-systolic diameter, IVS= Interventricular septum 
thickness, PWT= left ventricular posterior wall thickness, LVMI= left ventricular mass index.
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Table 5. Systolic and diastolic function variables by echocardiography and Doppler 
tissue imaging for healthy controls and patients with primary hyperparathyroidism 
before and 15±4 months after parathyroidectomy. 
 
Variable 
 
 
Controls PHPT cases P 
 
n=51 
Baseline 
n=51(35♀) 
Follow-up 
n=50(34♀) 
PHPT 
baseline 
vs. 
 controls 
PHPT  
baseline 
vs. 
follow-up 
Systolic Variable      
S´-RV (cm/s) 
(13.5±1.7)
1
 
13.85±1.77 
 
14.23±1.85 13.48±1.79 ns <0.05 
S´-IVS (cm/s) 
(7.7±1.7)
2
 
8.23±1.00 
 
8.48±0.96 7.97±0.85 ns <0.05 
S´-LVL (cm/s) 
(8.5±2.2)
2
 
9.80±1.89 
 
9.61±2.05 8.87±1.63* ns <0.05 
EF (%)  65.29±6.17
 a
 66.18±5.78
 a
 65.75±4.84
 a
 ns ns 
FS (%) 36.29±5.14
 a
 37.02±4.33
 a
 36.46±3,81
 a
 ns ns 
AV- plane RV (cm) 2.64±0,32 2.58±0.37 2.50±0.39 ns ns 
AV-plane IVS (cm) 1.44±0.20 1.42±0.18 1.39±0.19 ns ns 
AV-plane LV (cm) 1.57±0.21 1.55±0.18 1.55±0.18 ns ns 
Diastolic Variable      
E-wave (cm/s) 80.18±14.44 75.76±15.09 75.77±13.47 ns ns 
A-wave (cm/s) 59.59±12.48 60.58±15.27 61.41±12.70 ns ns 
E/A 1.39±0.33 1.30±0.34 1.27±0.28 ns ns 
DT (ms) 197.9±22.6 199.7±27.9 200.8±29.3 ns ns 
IVRT (ms) 82.36±16.20 86.67±18.42 86.32±19.42 ns ns 
PVs / PVd 1.16±0.27 1.22±0.34 1.21±0.32 ns ns 
E/ E´ Septal 7.81±1.73 7.69±1.74 7.54±1.58 ns ns 
E/ E´ Lateral 6.38±1.43 6.35±1.84 6.50±1.61 ns ns 
 
a
 n=49–50. Values are shown as mean ±SD. S´= the regional peak systolic myocardial velocities measured by DTI, 
RV= right ventricular wall, IVS= interventricular septum, LVL= left ventricular lateral wall, EF= ejection 
fraction, FS= fractional shortening. AV-Plane= atrioventricular plane displacement, E-wave= early transmitral 
diastolic flow velocity, A-wave= flow velocity during atrial contraction, DT= deceleration time, PVs= systolic 
pulmonary vein velocity, PVd= diastolic pulmonary vein velocity. E/ E´ = a ratio of early transmitral diastolic flow 
velocity (E) and early diastolic velocity recorded by DTI (E´) in the mitral annulus. 
1
 The reference for published 
normal values for DTI myocardial velocities for RV 
146
. 
2
 The reference for published normal values for DTI 
myocardial velocities for LV 
147
. * The peak systolic velocity in the lateral part of the mitral annulus was lower in 
patients after PTX compared to controls, P<0.05. 
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4.4 VASCULAR ULTRASOUND AND PULSE-WAVE ANALYSIS  
(STUDY III) 
The results of vascular ultrasound and pulse-wave variables are summarized in Table 6. 
AI% did not differ between patients and controls and did not change after PTX, neither 
did the estimated aortic blood pressure. We found no differences between patients and 
controls regarding IMTcca or lumen of the CCA and no changes were seen during 
follow-up. IM-GSM values did not differ and there was no significant change after 
PTX. The IMTrad of the right radial artery did not differ between the groups and was 
unchanged at follow-up. While the radial artery lumen diameter was similar to that of 
controls, a marginal increase in LDrad was noted after one year (p<0.05). Univariate and 
multivariate analyses of vascular variables to baseline data showed that AI% was related 
to age (beta 0.53, p<0.001) and inversely to weight (beta –0.41, p<0.001), while IMTcca 
was related to age (beta 0.55, p<0.001) and IM-GSM to weight (beta –0.33, p=0.02). 
Another multivariate analysis, adjusted for age and weight, of vascular variables (AI%, 
IMTcca and IM-GSM) in relation to biochemical data specifically abnormal in PHPT 
(PTH, Ca++, phosphate) showed no relation between vascular variables and PTH and 
Ca++; only a relation between AI% and phosphate (beta –0.22, P=0.004) was found. 
 
Table 6. Augmentation index and ultrasound measurements for healthy controls and 
patients with mild primary hyperparathyroidism before and 15±4 months after 
parathyroidectomy 
 
Variable 
 
Controls PHPT cases P 
 
n=48 (35♀) 
Baseline 
n=48 (35♀) 
 
Follow-up 
n=48 (35♀) 
 
PHPT 
baseline 
vs. 
 controls 
PHPT  
baseline 
vs. 
follow-up 
AI% 27.7±12.8 28.6±12.2 29.8±11.9 ns ns 
Ao SBP (mmHg) 109.8±15.3 114.4±17.3 114.8±15.8 ns ns 
Ao DBP (mmHg) 75.0±9.7 78.1±11.3 78.0±8.7 ns ns 
IMTrad (mm) 0.255±0.053
a
 0.271±0.060
c
 0.271±0.046
b
 ns ns 
LDrad (mm) 1.87±0.35
a
 1.79±0.30
c
 1.90±0.38
b
 ns <0.05 
IMTcca (mm) 0.680±0.135 0.688±0.113 0.702±0.119 ns ns 
LDcca (mm) 5.94±0.62 6.03±0.45 6.03±0.47 ns ns 
IM-GSM  86.5±15.3 82.3±17.2 81.8±15.9 ns ns 
 
a
47, 
b
43, 
c
40–41. Values are shown as mean ±SD. AI= augmentation index, Ao SBP= aortic systolic 
blood pressure, Ao DBP= aortic diastolic blood pressure, IMTrad = intima media thickness in right radial 
artery, LDrad= lumen diameter in right radial artery, IMTcca= intima media thickness in both left end 
right common carotid artery, LDcca= lumen diameter in common carotid artery, IM-GSM= intima media 
grey scale median in both left end right common carotid artery. 
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4.5 VITAMIN D AND CARDIOVASCULAR RISK MARKERS (STUDY IV) 
The serum 25-OH-D level was significantly lower in patients compared to controls at 
baseline and increased postoperatively, Table 7. Preoperative vitamin D deficiency (25-
OH-D < 50 nmol/L) was found in 77% of the patients (n=37/48) compared to 20% of 
the controls, (n=9/46). Another 21 % of the patients (n=10/48) and 59% of the controls 
(n=27/46) had insufficient vitamin D levels (50 > 25-OH-D < 75 nmol/L). At follow-up 
15±4 months after PTX, 40% (n=19/48) of the patients were still vitamin D deficient 
and 33% (n=16/48) were vitamin D insufficient. Except for a higher postoperative PTH 
level, patients with 25-OH-D levels below 50 nmol/L did not differ from those above 
this level as regards BMI, age, Ca++ and GFR in relation to vitamin D status, Table 8.  
 
The distributions of PTH and calcium in relation to vitamin D are illustrated in Figure 
10 and Figure 11. Postoperatively, 25-OH-D was inversely correlated to the PTH level 
(r= –0.34; P<0.05). Seven patients had elevated PTH levels at follow-up (range 68–92 
ng/L) in combination with normal Ca++ (range 1.20–1.31 mmol/L). The mean 25-OH-
D level was significantly lower in patients with a persistently elevated PTH level 
compared to those with normal PTH level at follow-up (25-OH-D; 45±19 vs. 61±19 
nmol/L; p<0.001); 5 of 7 patients had a 25-OH-D level below 50 nmol/L.  
 
The level of ALP was higher in PHPT patients compared to the healthy controls and 
correlated to the PTH and the Ca++ levels (r=0.53, p<0.001) as well as inversely to 25-
OH-D (r= –0.33, p<0.01) and decreased significantly after PTX, Table 7. 
 
The TG level was slightly higher in patients compared to controls; otherwise there were 
no differences between the groups regarding age, BMI, coagulation, inflammatory, 
metabolic and lipid markers, Table 7. After PTX, TG level decreased slightly, while 
BMI, apo-B and hs-CRP increased in patients. The level of calcium correlated to 
VWF:Ag (r=0.33, p<0.05) and the TG level correlated to PAI-1 activity (r=0.44, 
p<0.01).   
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Table 7. Vitamin D status and cardiovascular risk markers for healthy controls and 
patients with primary hyperparathyroidism before and 15±4 months after 
parathyroidectomy. 
 
Variable Controls PHPT cases P value 
 
n=49(35♀) 
 
Baseline 
n=49(35♀) 
 
Follow-up 
n=49(35♀) 
 
PHPT 
baseline 
vs. 
controls 
PHPT 
baseline 
vs. 
follow-up 
P-ALP (< 1.9 µkat/L) 0.91±0.24
c
 1.34±0.42
 c
 1.08±0.85
a
 <0.001 <0.001 
S-25-OH-D  
(75–250 nmol/L) 
64.6±20.8
a
 40.1±16.5
a
 58.9±19.5
a
 <0.001 <0.001 
S-Cholesterol 
(3.9–7.8 mmol/L) 
5.71±1.02
a
 5.76±0.80
a
 5.83±0.89 ns ns 
S-TG  
(0.45–2.6 mmol/L) 
0.86±0.43
a
 1.04±0.60
a
 0.94±0.50 <0.05 <0.05 
S-Apo-A1  
(1.10–2.10 g/L) 
1.73±0.31
a
 1.71±0.33
a
 1.68±0.28 ns ns 
S-Apo-B  
(0.50–1.70 g/L) 
1.02±0.21
a
 1.01±0.18
a
 1.06±0.16 ns <0.01 
Apo-B/Apo-A1 (<1) 0.61±0.14
 a
 0.62±0.18
a
 0.65±0.13 ns ns 
P-VWF  
(0.60–1.60 kIE/L) 
1.12±0.41
b
 1.06±0.36
a
 1.08±0.40
a
 ns ns. 
P-PAI-1 (<15 kIE/L) 9.34±6.32
b
 9.97±8.23
a
 8.69±7.41
a
 ns ns. 
P-hs-CRP (<3 mg/L) 1.13±1.21
a
 0.92±0.89
a
 2.00±5.00 ns <0.01 
P-Homocysteine  
(5.0–15 µg/L) 
9.25±3.00
a
 9.96±2.78
a
 9.78±2.64
a
 ns ns 
S-IGF-1  
(110–270 µg/L) 
136.3±52.9
a
 146.7±47.9
a
 142.7±67.7 ns ns 
 
a
n=45–48, bn=42–-43, cn=34–35, Values are shown as mean ±SD. ALP= alkaline phosphatase, 25-OH-
D= 25-hydroxyvitamin D, TG= triglyceride, Apo= apolipoprotein, VWF:Ag= von Willebrand factor, 
PAI-1= plasminogen activator inhibitor-1 activity, hs-CRP = high sensitive C-reactive protein, IGF-1= 
Insulin-like growth factor 1. 
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Table 8. Clinical and biochemical data (mean±SD) for patients with primary 
hyperparathyroidism, before and 15±4 months after parathyroidectomy in relation to 
vitamin D status.  
 
Variable 
 
PHPT baseline P PHPT follow-up P 
25-0H-D 
<50 nmol/L 
n=37 (26♀) 
25-0H-D 
>50 nmol/L 
n=11 (9♀) 
 25-0H-D 
    <50 nmol/L 
n=19 (16♀) 
25-0H-D 
>50 nmol/L 
n=29 (18♀) 
 
Age (yr.) 53.9±9.4 55.5±6.8 ns 56.6±8.4 54.6±9.1 ns 
BMI (kg/m
2
)  24.0±2.8 23.9±3.4 ns 25.3±2.9 24.2±3.5
 a 
ns 
GFR (mL/min) 104.0±23.2 91.6±15.0 ns 105.7±27.2 102.5±28.2
a
 ns 
S-Ca++(mmol/L) 1.46±0.07 1.45±0.03 ns 1.26±0.04 1.25±0.05 ns 
P-PTH (ng/L) 125.7±39.5 104.3±39.5 ns 57.2±15.3 44.8±14.0 P<0.01 
S-25-OH-D 
(nmol/L) 
33.4±10.1 62.5±14.0 P<0.001 41.0±6.7 70.6±15.8 P<0.001 
 
a 
n=27–28. BMI= body mass index, GFR= glomerular filtration rate according to Cockroft-Gault’s 
formula: GFR=(140 − age in yr) x (weight in kg/P-creatinine) x (1.23 in men, 1.04 in women), Ca++= 
ionized calcium, PTH= parathyroid hormone, 25-OH-D= 25-hydroxyvitamin D. Vitamin D deficiency 
defined as 25-OH-D < 50 nmol/L.
 
 
 
 
 
 
Figure 10. The distribution of 25-OH-D and parathyroid hormone (PTH) levels for the whole group of 
PHPT patients and the healthy control subjects 
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Figure 11.  The distribution of 25-OH-D and the ionized calcium levels for the whole group of PHPT 
patients and the healthy control subjects. 
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5 DISCUSSION 
 
The major goal of this thesis was to analyze the extent and nature of CV involvement in 
mild PHPT. We performed a prospective case-control study with a strict selection 
procedure. To avoid the influence of confounding factors, only patients and control 
subjects without known CV risk factors were included. The group of patients included 
in our study made up about one-tenth of all the PHPT patients treated with PTX at our 
clinic during the time period. We used advanced methods to evaluate CV structure and 
function. Vitamin D status and biochemical risk markers correlated to CV events were 
analyzed. We also performed an experimental study to analyze the acute effect of 
elevated PTH on vasodilatory function. 
 
5.1 STUDY I 
Measurement of the blood flow response to intra-arterial infusion of vasoactive agents 
using the invasive forearm model is the golden standard for assessing endothelial 
function in resistance arteries. The main advantage of this method is that it allows the 
evaluation of local effects on vasodilatory function since the risk of confounding by 
systemic effects is negligible. Experimental data suggest that PTH has vasodilatory 
properties, mediated directly through cAMP-dependent inhibition of L-type calcium 
channel currents in smooth muscle cells and/or through activation of endothelium-
derived nitride oxide production 
148, 149
. In the present study, PTH infusion into the 
brachial artery resulted in a locally elevated PTH and unchanged Ca++ level in the 
forearm but did not affect the vasodilatory reaction induced by metacholine (EDV) or 
nitroprusside (EIDV). We observed a numerical but not significant increase in both 
EDV and EIDV during PTH infusion.  
 
The systemic haemodynamic effects of PTH in humans are complex and have been 
studied in a few trials with contradictory results. While acute systemic PTH infusion 
caused hypotension 
35
, chronic infusion resulted in hypertension 
34
. In a study with 
systemic and local infusion of calcium in healthy subjects, Nilsson et al. observed a 
dose-related impairment in endothelial vasodilatory function, an increased SBP and a 
significant drop in PTH level during systemic hypercalcemia but not during local 
hypercalcemia 
40
.  
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The results from these studies support the hypothesis that the main hemodynamic 
actions of PTH are mediated indirectly through changes in the plasma calcium level 
and/or an impact on vasoactive hormones such as cortisol and the renin-aldosterone 
axis, 
35, 40, 150
. It should be emphasized that the number of subjects in our study was 
small and only major effects of PTH could be detected.  
 
5.2 STUDY II 
This study was conducted to evaluate BP, cardiac structure, function and the effect of 
PTX in patients with mild PHPT in comparison to healthy controls. We observed no 
differences in global systolic or diastolic function, or cardiac morphology in PHPT 
patients compared to controls. The BP and regional systolic myocardial velocities 
corresponded to normal values both at baseline and one year after PTX in all subjects. 
However, the patients had a slightly higher SBP compared to controls and both BP and 
regional systolic myocardial velocities decreased significantly after PTX. Our results 
indicate that PHPT patients had a higher systolic myocardial performance at baseline, 
which seems to be associated with PTH and Ca++ levels. The clinical significance of 
these findings is not clear. Hypothetically, a disease-related inotropic effect may result 
in increased vascular resistance and left ventricular workload which, if they persist, can 
partly explain some of the CV abnormalities seen in PHPT patients. Our hypothesis of 
a suprasystolic performance is supported by Almqvist et al., who observed a transient 
decrease in systolic and diastolic function variables in PHPT patients after PTX when 
the PTH and calcium levels had normalized 
65
. The authors interpreted this 
phenomenon as a result of the withdrawal inotropic effect of PTH.  
 
DTI is a sensitive echocardiographic method which allows early detection of even 
minor cardiac dysfunction 
151
. Mitral annulus velocity determined by DTI is a relatively 
preload-independent variable and is superior to conventional mitral Doppler indexes 
152
. To our knowledge, only two studies have used this method for evaluation of cardiac 
function in mild PHPT 
68, 153
. Similar to Walker et al., we did not find any abnormalities 
in LVMI or diastolic function in PHPT. Baykan et al. evaluated cardiac function in 
PHPT patients without CV risk factors and found signs of diastolic disturbances such as 
lower E, E/A ratio and prolonged IVRT in the PHPT group. We could not confirm 
these findings. A subgroup analysis revealed a prolonged IVRT in male cases but since 
the number of cases is only 16, the finding does not allow us to draw any conclusions.  
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The effect of PTX on BP has not been consistent in literature. The majority of previous 
data show no effect on BP in PHPT patients after PTX 
79, 88, 154
. However, other studies 
have shown decreased BP after PTX 
69, 91, 92
. We observed a minor decrease in both 
SBP and DBP in our patients after PTX.  
 
Data from observational studies involving more than 1 million individuals without 
previous vascular disease indicate that mortality from both ischemic heart disease and 
stroke increases from BP levels as low as 115/75 mmHg. For every 20 mmHg systolic 
or 10 mmHg diastolic increase in BP, there is a doubling of mortality from both 
ischemic heart disease and stroke 
155
. Early adequate BP control is essential for 
prevention of future CV events before irreversible CV alterations accrue. BP-lowering 
treatment provides a proportional reduction in CV risk in hypertensive patients and also 
in normotensive high-risk patients 
156
.  
 
5.3 STUDY III 
In this ultrasound study of arterial function and structure in the carotid and radial 
arteries and endothelial function evaluated by PWA, we found no indications of 
vascular abnormalities in patients with mild PHPT without any known CV risk factors. 
Neither did PTX cause any differences in either our vascular indices of arterial wall 
thickness or vascular function. In addition to patients yielding much the same vascular 
findings as controls, our results were further strengthened by the absence of an effect on 
arterial measurements from total and Ca++ and PTH.  
 
Increased AI% has been reported in mild PHPT 
66, 67
. In contrast to previous findings, 
AI% was normal in our patients and did not differ from controls.  
 
Data regarding carotid vascular abnormalities in PHPT are conflicting; while some 
have reported increased IMTcca in PHPT patients 
76, 80
, others have not found any 
disturbances 
77, 78
. Both severity of PHPT and coexisting CV diseases and risk factors 
play an important role in the development of cardiovascular complications and explain 
the conflicting findings in the literature. In our study with mild PHPT and careful 
exclusion of CV risk we did not observe an increased IMT or any other vascular 
abnormalities compared to controls. Our results are supported by Fallo et al., who 
compared PHPT patients with and without CV risk factors to healthy controls and 
found increased IMTcca only in patients with concomitant CV risk factors.  
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Our conclusions were substantiated by data from innovative techniques, such as grey 
scale median for the evaluation of echogenicity of the carotid intima media, and high 
resolution ultrasound for measurement of intima thickness in the radial artery. To our 
knowledge, this is the first time these kinds of technique have been used for this 
purpose in patients with mild PHPT. Previous data suggest that high resolution 
ultrasound allows measurement of very thin structures, such as intima of the carotid 
artery wall in rats, showing a significant relationship between intima thickness and the 
histopathology of intima of the carotid artery wall 
157
. Information regarding the 
composition and characteristics of the carotid artery wall can be obtained by using IM-
GSM technique. Earlier data have shown that IM-GSM in CCA is closely related to the 
echogenecity of the carotid plaques and that the echolucency of the carotid intima-
media is related to several CV risk factors 
158, 159
. Our results did not show any 
abnormalities in the structural properties of the carotid and radial arteries. 
 
5.4 STUDY IV 
The main objective of this study was to evaluate vitamin D status and biochemical risk 
markers correlated to CV events in patients with mild PHPT without other known CV 
risk factors. Except for a higher prevalence of vitamin D deficiency and slightly higher 
TG levels, biomarkers predicting CV diseases did not differ between healthy controls 
and patients. PTX had an overall positive effect on TG level and vitamin D status.  
 
In line with previous findings 
10, 160, 161
, vitamin D deficiency (serum 25-OH-D <50 
nmol/L) was more common in our patients with PHPT (77%) compared to their well-
matched controls (20%) from the same geographic area. The level of 25-OH-D was 
significantly increased at follow-up 15±4 months after PTX, though 40% of the patients 
were still vitamin D deficient. Vitamin D deficiency has been suggested to account for 
a significant number of patients who exhibit normocalcemic PTH elevation after 
successful PTX 
162, 163
. This may explain the persisting postoperative normocalcemic 
PTH elevation in combination with lower 25-OH-D levels in a small group of our 
patients.  
 
One weakness of our study could be that we did not analyze 1,25(OH)2D levels. 
However, the level of 25-OH-D, but not 1,25(OH)2D, has been reported to be 
correlated to PTH secretion in PHPT and seems to be the best indicator for evaluation 
of vitamin D status 
164
. Furthermore, 25-OH-D is more stable than the active form, its 
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circulating level in serum is roughly 500-1000 x that of 1,25(OH)2D and it correlates 
well with the biological effects of vitamin D 
27
. 
 
The preoperative elevation of serum ALP in our PHPT patients, which correlated with 
the PTH and Ca++ levels, could be an indication of an accelerated bone turnover, 
which has been shown in other studies 
165
.  
 
Few trials have evaluated the level of CV risk markers such as VWF, PAI-1 and hs-
CRP in PHPT patients; in keeping with these, we did not observe any abnormalities 
111, 
116
. An unexpected finding in our study was the increased hs-CRP level after PTX. The 
clinical significance of this finding is unclear. Plasma hs-CRP levels are influenced by 
many factors, such as trauma and infection 
166
. To avoid confounding factors, 
evaluation of hs-CRP on two separate occasions a few weeks apart is recommended; 
failure to do this was a weakness of our study. 
 
Dyslipidemia in mild PHPT has been observed in a few trials 
5, 108, 111
. The TG levels 
were slightly higher in our patients compared to controls but within the reference range 
and they decreased after PTX. Otherwise there were no inter-group differences in lipid 
status. The discrepant results could partly be explained by the presence of CV risk 
factors in previous studies.  
 
5.5 GENERAL DISCUSSION 
PHPT is a common endocrine disorder. The clinical profile of the disease has 
undergone a striking change in developed countries, from a severe symptomatic disease 
with typical target organ involvement (bone and kidneys) to an almost asymptomatic 
disorder with no obvious symptoms or signs traditionally associated with the disease. 
There is a broad consensus that patients with biochemically confirmed PHPT and 
classical symptoms from bone and kidneys should be offered parathyroid surgery. 
However, the indication for parathyroid surgery in so-called “asymptomatic” patients 
without any traditional PHPT symptoms is still debated. One reason for this 
controversy is the difficulty in predicting which patients will have disease progression 
or would benefit from early surgery to avoid future complications. Although patients 
with PHPT often complain of neurocognitive and psychiatric symptoms like memory 
disturbances, fatigue, anxiety and depression, neuropsychiatric symptoms are still not 
generally accepted as indications for parathyroid surgery. Neither are the presence of 
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CV diseases or prevention of future CV complications commonly accepted as 
indications for parathyroid surgery.  
 
The long-term effects of undiagnosed or conservatively treated PHPT are still largely 
unknown. Long-term observational data show evidence of biochemical and 
densitometric stability in the majority of the patients in the first 8–12 years. However, 
approximately 25 % of the patients show evidence of disease progression, worsening of 
the biochemical profile after 12 years, and densitometric progression after 8 years 
18
. 
Furthermore, data regarding the extent of CV complications and reversibility after 
surgical cure in mild asymptomatic PHPT are limited. The latest international 
workshop for asymptomatic PHPT emphasized that further investigations regarding CV 
aspects in mild PHPT are needed 
9
.  
 
The term mild PHPT is frequently used in the literature but there is no generally 
approved definition. We defined mild hyperparathyroidism as plasma calcium less than 
2.75 mmol/L and/or the absence of overt symptoms related to hypercalcemia. The 
majority of our patients had plasma calcium levels below 2.75 mmol/L; only 5 patients 
had levels between 2.76–2.97 mmol/L at the time of inclusion. The main objective of 
this thesis was to study how mild hyperparathyroidism affects the CV function. We 
applied a strict selection to exclude patients with known CV disease and risk factors or 
medication that could affect CV function. Only about one-tenth of all the PHPT 
patients treated at our clinic met the inclusion criteria for the study. The strict selection 
is the main strength of our study and furthermore adds to the accuracy of our findings 
since other confounding factors are excluded. However, it might also be considered as a 
weakness, since our results may not be extended to the large PHPT population in 
general where comorbidity is common. It is most likely that PHPT may potentiate the 
negative effects of co-existing risk factors 
167
. 
 
Despite usage of sensitive methods for evaluation of the CV system, we found no 
obvious signs of CV involvement in our patients. However, we did observe subtle 
differences such as slightly higher SPB and TG levels in the PHPT patients compared 
to controls. Our patients had also a “supersystolic performance”, with higher systolic 
myocardial velocities, and higher systolic and diastolic BP. Surgical cure had an overall 
positive effect on all these factors. The clinical significance of these subtle findings is 
not clear. Hypothetically, if the disease-related “supersystolic” condition persists for a 
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long time, it might result in an increased vascular resistance and cardiac workload that 
may contribute to future CV complications. Population studies support that even a 
small reduction in BP could have a major public health impact on the risk of coronary 
heart disease and stroke events 
168
.  
 
A very large proportion of our patients (77%) had vitamin D deficiency. PTX had a 
positive effect on vitamin D status. However, 40% of our patients remained vitamin D 
deficient after successful cure. The clinical consequence of this finding is not clear. 
Vitamin D deficiency represents an important new CV risk factor and has been 
associated with increased CV morbidity 
96, 169
. However, the coupling between vitamin 
D deficiency and CV morbidity is not fully understood and there is no available 
evidence that vitamin D supplementation might prevent future CV events.  
 
It is reasonable to believe that the adverse effect of the hyperparathyroid condition may 
be amplified in the presence of other CV risk factors 
167, 170, 171
. It is also reasonable to 
assume that adequate treatment of PHPT and the coexisting risk factors may improve 
the CV outcome. However, based on our results, we have no evidence that CV 
complications can be prevented by parathyroid surgery in PHPT patients without 
known CV diseases and risk factors. If just the CV aspect is taken into consideration, 
the indication for surgery in this subgroup of PHPT patients is therefore not clear-cut.  
 
5.6 FUTURE PERSPECTIVES 
The natural history of PHPT in conservatively treated patients with asymptomatic mild 
disease is poorly investigated. To identify risk patients who may benefit from early 
surgical treatment, future randomized studies, comparing the long-term effects of 
conservative follow-up and parathyroid surgery respectively, on wide health aspects are 
required. Furthermore, the influence of vitamin D deficiency and CV aspects in PHPT 
need further investigation, as do how and when to optimize vitamin D status in PHPT 
patients with concomitant vitamin D deficiency.  
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6 CONCLUSIONS 
 
 Experimental acute elevation of the PTH level alone had no effect on 
endothelial vasodilatory function. 
 
Patients with mild PHPT without known CV risk factors had: 
 
 Normal global systolic and diastolic function and cardiac morphology but a 
higher systolic myocardial performance and blood pressure at baseline, which 
seems to be associated with PTH and Ca++ levels and decreased after PTX.  
 
 Normal arterial function and structure in the carotid and radial arteries. No 
differences were observed between cases and controls. Neither did PTX entail 
any differences in either our vascular indices of arterial wall thickness or 
vascular function. 
 
 Higher prevalence of vitamin D deficiency and a slightly higher TG level 
compared to controls. Otherwise there were no inter-group differences in 
coagulation, inflammatory metabolic and lipid status. PTX had an overall 
positive effect on TG level and vitamin D status. 
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7 POPULÄRVETENSKAPLIG SAMMANFATTNING 
(SWEDISH SUMMARY) 
 
Primär hyperparatyreoidism (bisköldkörtelöverfunktion, PHPT) är en vanlig sjukdom 
där ökad utsöndring av parathormon (bisköldkörtelhormon) medför förhöjda 
kalciumnivåer i blodet. PHPT orsakas oftast av en godartad tumör i en av 
bisköldkörtlarna. Cirka 1 % av den vuxna befolkningen och 3-4 % av kvinnorna efter 
klimakteriet drabbas. Idag upptäcks sjukdomen oftast av en slump i samband med 
rutinmässig blodprovstagning. Många patienter har nästan inga eller väldigt diffusa 
symptom som trötthet, irritabilitet minskad livsglädje och/eller minnesstörning. Den 
enda botbara behandlingen är kirurgiskt avlägsnande av onormal bisköldkörtelvävnad. 
 
Tidigare studier har visat ökad sjuklighet och dödlighet i hjärtkärlsjukdomar vid PHPT. 
Däremot vet vi väldigt lite om riskerna för hjärtkärlsjukdom i samband med mild 
PHPT. Denna osäkerhet beror delvis på att tidigare studier av PHPT har omfattat 
individer med olika svårighetsgrader av sjukdomen och som i stor utsträckning 
belastats även av andra riskfaktorer som kan ha påverkat resultaten.  
 
Huvudsyftet med våra studier i denna avhandling var att undersöka hjärtkärlfunktionen 
hos patienter med mild PHPT utan kända riskfaktorer för hjärtkärlsjukdom och 
analysera effekten av operation. Vi valde ut en grupp av patienter utan kända 
riskfaktorer som högt blodtryck, fetma, diabetes eller medicinering som påverkade 
hjärtkärlfunktionen. Endast någon tiondel av våra patienter med PHPT som genomgick 
operation under studieperioden uppfyllde dessa kriterier. Vi startade med att undersöka 
om kärlfunktionen i underarmen påverkades vid akut förhöjning av parathormonnivån 
hos friska individer.  
 
Studie I: Kärlfunktionen utvärderades med venös pletysmografi före och under 
infusion av parathormon i underarmsartär som medförde lokalt förhöjning av 
parathormonnivån i underarmen hos 10 friska individer. Vi kunde inte påvisa någon 
direkt inverkan av parathormon på kärlfunktionen.  
 
Studie II-IV: 51 patienter med mild PHPT och 51 slumpmässigt utvalda 
kontrollpersoner, matchade för ålder och kön deltog i studierna. Hjärtkärlfunktionen 
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undersöktes med känslig ultraljudsteknik. Vi analyserade nivåer av riskmarkörer för 
hjärtkärlsjukdomar (blodfetter, inflammatoriska och tromboemboliska markörer) samt 
D-vitamin i blodet.  
 
Våra studier visade att patienter med mild PHPT hade normal hjärtkärlfunktion jämfört 
med friska kontroller. Det fanns dock små skillnader mellan grupperna. Patienterna 
hade något högre systoliskt blodtryck och högre blodfetter jämfört med friska 
kontroller. D-vitaminbrist var mycket vanligare hos patienterna (77%) jämfört med 
kontrollerna (20%). Operation hade en positiv inverkan på blodtrycket, blodfetterna och 
D-vitaminnivåerna. Vi kan inte uttala oss om den kliniska betydelsen av dessa små 
skillnader mellan grupperna.  
 
Sammanfattningsvis fann vi inte evidens för att patienter med mild PHPT utan kända 
riskfaktorer för hjärtkärlsjukdom löper ökad risk för hjärtkärlkomplikationer. Man 
måste vara klar över att den studerade gruppen utgör en höggradigt selekterad grupp av 
patienter med ”låg riskprofil”. Vår studiedesign tillåter oss inte att uttala oss om PHPT 
kan potentiera risken för hjärtkärlkomplikationer hos patienter med PHPT och 
samtidiga riskfaktorer för hjärtkärlsjukdom.  
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